Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Zaniboni

Showing results (11-20 of 233) with videos related to

Pageof 24
Sort By:
Immunotherapy|June 10, 2017
Immunotherapy for pancreatic cancer: present and futureFrancesca Aroldi, Alberto Zaniboni
Recenti Progressi in Medicina|January 19, 2016
[Regorafenib in patients with metastatic colorectal cancer: a review and an update]Alberto Zaniboni, Giovanni Mansueto
Journal of Gastrointestinal Oncology|May 15, 2018
Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospectsPiercarlo Saletti, Alberto Zaniboni
Cancer Immunology, Immunotherapy : CII|November 9, 2020
Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literatureFausto Meriggi, Alberto Zaniboni
Critical Reviews in Oncology/Hematology|September 20, 2005
Non-small-cell lung cancer in the elderlyFausto Meriggi, Alberto Zaniboni
Reviews on Recent Clinical Trials|December 25, 2012
Fentanyl for breakthrough cancer pain: where are we?Fausto Meriggi, Alberto Zaniboni
Recenti Progressi in Medicina|April 20, 2016
[Ramucirumab-paclitaxel as second-line therapy for advanced gastric cancer: Poliambulanza experience]Francesca Aroldi, Chiara Ogliosi, Alberto Zaniboni
Recenti Progressi in Medicina|April 12, 2017
[Cetuximab in association with an oxaliplatin-based chemotherapy as first-line treatment of metastatic colorectal cancer.]Fausto Petrelli, Antonio Ghidini, Alberto Zaniboni
Biomedicines|May 16, 2023
Low-Dose Immunotherapy: Is It Just an Illusion?Fausto Meriggi, Alberto Zaniboni, Anna Zaltieri
World Journal of Gastroenterology|May 19, 2021
Pancreatic adenocarcinoma: Beyond first line, where are we?Sara Cherri, Silvia Noventa, Alberto Zaniboni
Pageof 24

Showing results (11-20 of 233) with videos related to

Sort By:
Pageof 24
Immunotherapy|June 10, 2017
Immunotherapy for pancreatic cancer: present and futureFrancesca Aroldi, Alberto Zaniboni
Recenti Progressi in Medicina|January 19, 2016
[Regorafenib in patients with metastatic colorectal cancer: a review and an update]Alberto Zaniboni, Giovanni Mansueto
Journal of Gastrointestinal Oncology|May 15, 2018
Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospectsPiercarlo Saletti, Alberto Zaniboni
Cancer Immunology, Immunotherapy : CII|November 9, 2020
Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literatureFausto Meriggi, Alberto Zaniboni
Critical Reviews in Oncology/Hematology|September 20, 2005
Non-small-cell lung cancer in the elderlyFausto Meriggi, Alberto Zaniboni
Reviews on Recent Clinical Trials|December 25, 2012
Fentanyl for breakthrough cancer pain: where are we?Fausto Meriggi, Alberto Zaniboni
Recenti Progressi in Medicina|April 20, 2016
[Ramucirumab-paclitaxel as second-line therapy for advanced gastric cancer: Poliambulanza experience]Francesca Aroldi, Chiara Ogliosi, Alberto Zaniboni
Recenti Progressi in Medicina|April 12, 2017
[Cetuximab in association with an oxaliplatin-based chemotherapy as first-line treatment of metastatic colorectal cancer.]Fausto Petrelli, Antonio Ghidini, Alberto Zaniboni
Biomedicines|May 16, 2023
Low-Dose Immunotherapy: Is It Just an Illusion?Fausto Meriggi, Alberto Zaniboni, Anna Zaltieri
World Journal of Gastroenterology|May 19, 2021
Pancreatic adenocarcinoma: Beyond first line, where are we?Sara Cherri, Silvia Noventa, Alberto Zaniboni
Pageof 24